ADMS News Alert Adamas Pharmaceuticals Inc. (ADMS) 13.97 12/12/2014

New Post Public Reply Private Reply Replies (0) Message Board

Dec 13, 2014 at 12:42 AM

Adamas Pharmaceuticals Inc. (ADMS) 13.97 $ADMS

First patient enrolled in Acorda Phase 3 PD trial
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 7:06AM CST

IPXL: 31.16 (-0.74), ADMS: 13.97 (-0.42), TEVA: 55.92 (-0.92), ACOR: 38.70 (+0.06), PRTA: 18.15 (-0.34), NDRM: 7.19 (-0.17)

Adamas Pharmaceuticals wins six additional US patents for amantadine HCl
M2 - Wed Dec 03, 8:26AM CST
Pharmaceutical company Adamas Pharmaceuticals (NasdaqGM:ADMS) reported on Tuesday that it has received six additional patents in the US, bringing the total number of issued patents for amantadine-based controlled-release products to nine, with 12 more applications pending.
ADMS: 13.97 (-0.42)

Adamas Pharmaceuticals Issued Six Additional U.S. Patents
GlobeNewswire - Tue Dec 02, 8:01AM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) announced the issuance of six additional US patents (US 8,889,740; US 8,895,614; US 8,895,615; US 8,895,616; US 8,895,617 and US 8,895,618), bringing the total number of issued patents for amantadine-based controlled-release products owned by Adamas to nine, with 12 more applications pending. The newly issued patents include both composition of matter claims and claims covering methods for treatment of neurological diseases, including Parkinson's disease, related to the pharmacokinetic profile of amantadine HCl.
ADMS: 13.97 (-0.42)

Adamas Pharmaceuticals to Present at Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 18, 11:00AM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, PhD., Chief Executive Officer, will present at the 26 Annual Piper Jaffray Healthcare Conference in New York on Wednesday, December 3, 2014 at 3:30 PM Eastern Time.
ADMS: 13.97 (-0.42)

Adamas Pharmaceuticals to Present at 2014 Credit Suisse Healthcare Conference
GlobeNewswire - Wed Nov 05, 3:02PM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, PhD., Chief Executive Officer, will present at the 2014 Credit Suisse Healthcare Conference in Phoenix, AZ on Tuesday, November 11, 2014 at 7:30 AM Mountain Time.
ADMS: 13.97 (-0.42)

Adamas Pharma misses by $0.13, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 4:44PM CST

ADMS: 13.97 (-0.42)

Adamas Reports Third Quarter 2014 Financial Results
GlobeNewswire - Tue Nov 04, 3:03PM CST
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported a net loss attributable to common stockholders of $9.6 million, or $0.57 per share, for the quarter ended September 30, 2014. In the same period last year, the company reported a net loss attributable to common stockholders of $3.4 million, or $0.36 per share. Adamas ended the current quarter with $137.5 million in cash and cash equivalents, compared to $85.6 million at December 31, 2013.
ADMS: 13.97 (-0.42)

Adamas Pharmaceuticals Expands Its Phase 3 Program With ADS-5102 for the Treatment of Levodopa-induced Dyskinesia (LID) in Patients With Parkinson's Disease
GlobeNewswire - Tue Oct 28, 3:01PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it has initiated an additional Phase 3 safety and efficacy study evaluating ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. ADS-5102, an investigational agent, is a high dose, controlled-release version of amantadine HCl administered once daily at bedtime.
ADMS: 13.97 (-0.42)

Genervon ALS drug shows encouraging results
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:27AM CDT

BIIB: 344.49 (+2.16), MNOV: 3.60 (+0.18), CHTP: 6.52 (-0.03), ADMS: 13.97 (-0.42), ACOR: 38.70 (+0.06), BCLI: 2.90 (-0.06), BSX: 13.00 (+0.11), IPXL: 31.16 (-0.74), AVNR: 16.95 (-0.02), ACAD: 32.53 (-0.10), CVTS: (), MRK: 57.72 (-1.62), TEVA: 55.92 (-0.92), PRTA: 18.15 (-0.34), PRAN: 1.86 (-0.05), FOLD: 8.15 (+0.18), CUR: 2.58 (-0.09)

OTC Daily Alert Stock Watch - Adamas Pharmaceuticals, Inc., (NASDAQ: ADMS)
WorldStockWire - Sat Oct 18, 11:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ADMS: 13.97 (-0.42)

5 Big-Volume Stocks to Trade for Big Breakouts
at The Street - Thu Oct 02, 8:20AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
MDVN: 106.86 (-1.16), RCAP: 11.81 (-0.10), ADMS: 13.97 (-0.42), TRGP: 92.56 (-0.45), NRG: 26.66 (-0.26)

Adamas Pharmaceuticals Announces Management Changes
GlobeNewswire - Wed Aug 13, 3:05PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced changes to its management team.
ADMS: 13.97 (-0.42)

Adamas Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 07, 3:44PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported net income attributable to common stockholders of $16.4 million, or $0.88 per share on a fully diluted basis, for the quarter ended June 30, 2014. In the same period last year, the company reported a net loss attributable to common stockholders of $3.4 million, or $0.35 per share on a fully diluted basis. The difference between the two periods was primarily the result of the recognition of revenue associated with the collaboration with Forest Laboratories, Inc. (acquired by Actavis plc in July 2014).
ADMS: 13.97 (-0.42), FRX: 99.00 (-0.77)

Adamas Pharmaceuticals receives US Patent No. 8,796,337 for ADS-5102 and amantadine product candidates
M2 - Wed Aug 06, 5:48AM CDT
Specialist pharmaceutical company Adamas Pharmaceuticals (NasdaqGM:ADMS) reported on Tuesday the receipt of the US Patent No. 8,796,337, entitled "Composition and Method For Treating Neurological Disease" from the US Patent and Trademark Office (USPTO).
ADMS: 13.97 (-0.42)

United States Patent Issued to Adamas Pharmaceuticals
GlobeNewswire - Tue Aug 05, 3:08PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS), today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,796,337, entitled "Composition and Method For Treating Neurological Disease." The claims of this patent are directed towards methods for treating human subjects with amantadine therapy, including Adamas' lead product candidate ADS-5102 and similar amantadine-based products.
ADMS: 13.97 (-0.42)

Adamas Pharmaceuticals, Inc. (ADMS) in Focus: Stock Rises 7.04% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 7:44AM CDT
Adamas Pharmaceuticals, Inc. (ADMS) was a big mover last session, as the company saw its shares rise 7% on the day.
MNK: 94.72 (-0.36), AKRX: 41.24 (+0.38), ADMS: 13.97 (-0.42), RDY: 53.90 (-0.68)

Forest Laboratories Nabs Pediatric Exclusivity for Namenda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 12:20PM CDT
With an additional six months of pediatric exclusivity in the U.S., generic versions of Forest's (FRX) Namenda IR will now enter the market in Jul 2015.
ACT: 259.00 (-4.00), GILD: 104.13 (-0.18), ADMS: 13.97 (-0.42), FRX: 99.00 (-0.77)

Adamas Pharmaceuticals To Present At JMP Securities Healthcare Conference 2014
PR Newswire - Mon Jun 16, 3:01PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that Gregory T. Went, PhD., Chief Executive Officer, will present at the JMP Securities Healthcare Conference 2014 in New York on Tuesday, June 24, 2014 at 1:00 PM Eastern Standard Time.
ADMS: 13.97 (-0.42)

Will Forest Labs Retain Namenda Market Share? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 13, 11:00AM CDT
Forest Laboratories, Inc. (FRX) has postponed the final phase of switching to late 2014 and intends to continue marketing Namenda IR till the fall of 2014.
ACT: 259.00 (-4.00), ADMS: 13.97 (-0.42), ANIP: 54.28 (+2.33), FRX: 99.00 (-0.77)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Firehawk Defense Secures $150M, Valuation Hits $1.4B

Firehawk Defense Lands Major Funding Think about it—Firehawk Defense, a gutsy Dallas-based new-kid-on-the-block, just snagged a whopping $150 million in fresh funding. The news? Their valuation's now sitting pretty at $1.4 billion. Not peanuts, by any means. For a company in the artillery game, that's a blast of an announcement. They're predicting they'll become the big...

Infrastructure Capital's ETFs: Dividend Windfall

Payout Boost for Income-Hungry Investors You know, it ain't every day you hear about dividend increases across the board. But Infrastructure Capital Advisors, that investment management powerhouse, is dishing out more dough to its investors through a dividend uptick. They're bumping up the payouts on not just one, but four of their ETFs: Bond Income ETF (BNDS), Equity...

RKD Groups' New Initiative: Monthly Giving Accelerator

Something’s cooking in the nonprofit realm, and it ain’t business as usual. RKD Group is stirring the pot big time with their latest endeavor: the Monthly Giving Accelerator. They’ve roped in Dana Snyder, who’s got a track record working with big guns like the Canadian Red Cross and Movember. Let’s just say she's got a Ph.D. in monthly donations. What’s the...

Shira Goodman Joins APEI Board: New Direction?

A New Chapter for American Public Education Alright, sit tight because this one’s got layers. American Public Education, Inc. (Nasdaq: APEI) just shook up its board by bringing in Shira Goodman, the former CEO of Staples. This move isn't just swapping one name for another; it’s about bolstering leadership at a time when strategic decisions are pivotal. Who is Shira...

Billd's Flex Line: Game-Changer for Subcontractor Credit

Billd's Bold Move Across America Forget piecemeal rollouts; Billd's taking their latest brainchild, Flex Line, right into the heart of America's subcontractor landscape. This isn't some flash-in-the-pan financial offering, either—it's a heavy-hitter poised to shake up the way subcontractors wrangle their working capital. We're talking about a line of credit that's as...

MetaOptics Bolsters Strategies with Buy-Back Mandate

Strategic Moves by MetaOptics If you thought the optics game was settled ages ago, think again. Today, MetaOptics Ltd (Catalist: 9MT), from sunny Singapore, is stirring up the pot with their latest game plan—a freshly minted Share Buy-Back Mandate. Shareholders at their general meeting were all thumbs up, and that's no surprise given what's on the table. Aim for...

Microplastics Found in Human Blood: Alarming Evidence

An Unsettling Discovery in Our Veins Microplastics in the blood? Yep, you read that right, and it’s not some sci-fi horror story—it’s today’s harsh reality. A riveting report from the likes of the Plastic Pollution Coalition and the Canadian Association of Physicians for the Environment has thrown a bucket of cold water on us. They uncovered microplastics in 96%...

Farizon SV 2027 Debuts in France Amid Market Shifts

A New Entry in the European Delivery Market The game's changing in European delivery, folks, and you better believe Geely Farizon's got a stake in it. Rolling out their all-electric Farizon SV Model Year 2027 at the world-renowned Marché International de Rungis, these folks are nothing if not ambitious. Nestled in the heart of the produce distribution world, Rungis...

D-Wave Faces Class Action: Investors Seek Justice

When you hear a heavyweight like D-Wave Quantum Inc. finding itself tangled in a securities fraud lawsuit, you know there’s something big brewing. D-Wave Quantum Inc. NASDAQ: QBTS is under the spotlight and the clock is ticking. If you've dipped your toes into their stock between February 26, 2026, and August 25, 2026, chances are, this might be your ticket to seek some...

Astemo Flexes Aftermarket Muscles at 2026 AAPEX & SEMA

Ah, nothing gets car enthusiasts more revved up than a good old-fashioned auto show unveiling. Astemo Americas is strutting its stuff at the 2026 AAPEX and SEMA shows, and they're not just shooting the breeze—this company has got some serious aftermarket muscle to flex. Pumping Up the Aftermarket Game Astemo's not sitting on its hands when it comes to expanding its...